A Phase I/II randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Pimple patches seem to be soaring in popularity—and a newly invented ...

- The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...

The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...

A dengue virus vaccine candidate has passed an important milestone, with promising results in animal model testing providing hope to the 390 million people infected every year. The University of ...

Vaccine experts tend to be a serious bunch, but many are downright giddy about vaccine clinical trial results presented last week at a medical conference in Seattle. The actual vaccine isn't new — ...

Add Popular Science (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.

ANDERNACH, Germany & BALLERUP, Denmark--(BUSINESS WIRE)--LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, ...

A COVID-19 patch developed in Australia was found to be more effective than vaccines administered through a needle. UQ See more of our coverage in your search results. Add The New York Post on Google ...

- The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...